Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 126

1.

Serum amyloid A and Janus kinase 2 in a mouse model of diabetic kidney disease.

Dieter BP, Meek RL, Anderberg RJ, Cooney SK, Bergin JL, Zhang H, Nair V, Kretzler M, Brosius FC, Tuttle KR.

PLoS One. 2019 Feb 14;14(2):e0211555. doi: 10.1371/journal.pone.0211555. eCollection 2019.

2.

Body Weight and eGFR during Dulaglutide Treatment in Type 2 Diabetes and Moderate-to-Severe Chronic Kidney Disease (AWARD-7).

Tuttle KR, Lakshmanan MC, Rayner B, Zimmermann AG, Woodward DB, Botros FT.

Diabetes Obes Metab. 2019 Feb 14. doi: 10.1111/dom.13668. [Epub ahead of print]

PMID:
30762290
3.

Sodium-Glucose Cotransporter 2 Inhibition and Diabetic Kidney Disease.

Alicic RZ, Neumiller JJ, Johnson EJ, Dieter B, Tuttle KR.

Diabetes. 2019 Feb;68(2):248-257. doi: 10.2337/dbi18-0007.

PMID:
30665953
4.

Development of an International Standard Set of Value-Based Outcome Measures for Patients With Chronic Kidney Disease: A Report of the International Consortium for Health Outcomes Measurement (ICHOM) CKD Working Group.

Verberne WR, Das-Gupta Z, Allegretti AS, Bart HAJ, van Biesen W, García-García G, Gibbons E, Parra E, Hemmelder MH, Jager KJ, Ketteler M, Roberts C, Al Rohani M, Salt MJ, Stopper A, Terkivatan T, Tuttle KR, Yang CW, Wheeler DC, Bos WJW.

Am J Kidney Dis. 2019 Mar;73(3):372-384. doi: 10.1053/j.ajkd.2018.10.007. Epub 2018 Dec 20.

5.

GLP-1 receptor agonists, CKD, and eGFR trajectory - Authors' reply.

Tuttle KR, Lakshmanan MC, Rayner B, Busch RS, Zimmermann AG, Woodward DB, Botros FT.

Lancet Diabetes Endocrinol. 2018 Oct;6(10):765. doi: 10.1016/S2213-8587(18)30239-0. No abstract available.

PMID:
30266182
6.

GLP-1 receptor agonists in diabetic kidney disease: from the patient-side to the bench-side.

Dieter BP, Alicic RZ, Tuttle KR.

Am J Physiol Renal Physiol. 2018 Dec 1;315(6):F1519-F1525. doi: 10.1152/ajprenal.00211.2018. Epub 2018 Aug 15.

PMID:
30110568
7.

Serum Calcification Propensity and Fetuin-A: Biomarkers of Cardiovascular Disease in Kidney Transplant Recipients.

Bostom A, Pasch A, Madsen T, Roberts MB, Franceschini N, Steubl D, Garimella PS, Ix JH, Tuttle KR, Ivanova A, Shireman T, Gohh R, Merhi B, Jarolim P, Kusek JW, Pfeffer MA, Liu S, Eaton CB.

Am J Nephrol. 2018;48(1):21-31. doi: 10.1159/000491025. Epub 2018 Jul 11.

PMID:
29996127
8.

Dulaglutide versus insulin glargine in patients with type 2 diabetes and moderate-to-severe chronic kidney disease (AWARD-7): a multicentre, open-label, randomised trial.

Tuttle KR, Lakshmanan MC, Rayner B, Busch RS, Zimmermann AG, Woodward DB, Botros FT.

Lancet Diabetes Endocrinol. 2018 Aug;6(8):605-617. doi: 10.1016/S2213-8587(18)30104-9. Epub 2018 Jun 14.

PMID:
29910024
9.

SGLT2 Inhibition for the Prevention and Treatment of Diabetic Kidney Disease: A Review.

Alicic RZ, Johnson EJ, Tuttle KR.

Am J Kidney Dis. 2018 Aug;72(2):267-277. doi: 10.1053/j.ajkd.2018.03.022. Epub 2018 Jun 14. Review.

PMID:
29866460
10.

Race in America: What Does It Mean for Diabetes and CKD?

Tuttle KR.

Clin J Am Soc Nephrol. 2018 Jun 7;13(6):829-830. doi: 10.2215/CJN.04890418. Epub 2018 May 24. No abstract available.

PMID:
29798886
11.

Serum Uromodulin: A Biomarker of Long-Term Kidney Allograft Failure.

Bostom A, Steubl D, Garimella PS, Franceschini N, Roberts MB, Pasch A, Ix JH, Tuttle KR, Ivanova A, Shireman T, Kim SJ, Gohh R, Weiner DE, Levey AS, Hsu CY, Kusek JW, Eaton CB.

Am J Nephrol. 2018;47(4):275-282. doi: 10.1159/000489095. Epub 2018 Apr 26.

PMID:
29698955
12.

Inflammatory Mechanisms as New Biomarkers and Therapeutic Targets for Diabetic Kidney Disease.

Alicic RZ, Johnson EJ, Tuttle KR.

Adv Chronic Kidney Dis. 2018 Mar;25(2):181-191. doi: 10.1053/j.ackd.2017.12.002. Review.

PMID:
29580582
13.

Diabetic Kidney Disease (c. 2018).

Tuttle KR.

Adv Chronic Kidney Dis. 2018 Mar;25(2):119-120. doi: 10.1053/j.ackd.2018.01.006. No abstract available.

PMID:
29580575
14.

JAK1/JAK2 inhibition by baricitinib in diabetic kidney disease: results from a Phase 2 randomized controlled clinical trial.

Tuttle KR, Brosius FC 3rd, Adler SG, Kretzler M, Mehta RL, Tumlin JA, Tanaka Y, Haneda M, Liu J, Silk ME, Cardillo TE, Duffin KL, Haas JV, Macias WL, Nunes FP, Janes JM.

Nephrol Dial Transplant. 2018 Nov 1;33(11):1950-1959. doi: 10.1093/ndt/gfx377.

15.

Medication Therapy Management after Hospitalization in CKD: A Randomized Clinical Trial.

Tuttle KR, Alicic RZ, Short RA, Neumiller JJ, Gates BJ, Daratha KB, Barbosa-Leiker C, McPherson SM, Chaytor NS, Dieter BP, Setter SM, Corbett CF.

Clin J Am Soc Nephrol. 2018 Feb 7;13(2):231-241. doi: 10.2215/CJN.06790617. Epub 2018 Jan 2.

16.

Action plan for optimizing the design of clinical trials in chronic kidney disease.

Perkovic V, Craig JC, Chailimpamontree W, Fox CS, Garcia-Garcia G, Benghanem Gharbi M, Jardine MJ, Okpechi IG, Pannu N, Stengel B, Tuttle KR, Uhlig K, Levey AS.

Kidney Int Suppl (2011). 2017 Oct;7(2):138-144. doi: 10.1016/j.kisu.2017.07.009. Epub 2017 Sep 20. Review.

17.

Reducing major risk factors for chronic kidney disease.

Luyckx VA, Tuttle KR, Garcia-Garcia G, Gharbi MB, Heerspink HJL, Johnson DW, Liu ZH, Massy ZA, Moe O, Nelson RG, Sola L, Wheeler DC, White SL.

Kidney Int Suppl (2011). 2017 Oct;7(2):71-87. doi: 10.1016/j.kisu.2017.07.003. Epub 2017 Sep 20. Review.

18.

Association of Serum Amyloid A with Kidney Outcomes and All-Cause Mortality in American Indians with Type 2 Diabetes.

Saulnier PJ, Dieter BP, Tanamas SK, McPherson SM, Wheelock KM, Knowler WC, Looker HC, Meek RL, Nelson RG, Tuttle KR.

Am J Nephrol. 2017;46(4):276-284. doi: 10.1159/000481269. Epub 2017 Sep 22.

19.

The Northwest Participant and Clinical Interactions Network: Increasing opportunities for patients to participate in research across the Northwestern United States.

Baldwin LM, Hassell L, Laukes C, Doyle M, Reedy A, Mollis B, Albritton S, Ciemins E, Coker R, Brant J, Tuttle KR, Baker L, Ramsey B.

J Clin Transl Sci. 2017 Apr;1(2):94-100. doi: 10.1017/cts.2016.18. Epub 2017 Apr 19.

20.

Diabetic Kidney Disease: Challenges, Progress, and Possibilities.

Alicic RZ, Rooney MT, Tuttle KR.

Clin J Am Soc Nephrol. 2017 Dec 7;12(12):2032-2045. doi: 10.2215/CJN.11491116. Epub 2017 May 18.

21.

Therapeutic Considerations for Antihyperglycemic Agents in Diabetic Kidney Disease.

Neumiller JJ, Alicic RZ, Tuttle KR.

J Am Soc Nephrol. 2017 Aug;28(8):2263-2274. doi: 10.1681/ASN.2016121372. Epub 2017 May 2. Review.

22.

Global kidney health 2017 and beyond: a roadmap for closing gaps in care, research, and policy.

Levin A, Tonelli M, Bonventre J, Coresh J, Donner JA, Fogo AB, Fox CS, Gansevoort RT, Heerspink HJL, Jardine M, Kasiske B, Köttgen A, Kretzler M, Levey AS, Luyckx VA, Mehta R, Moe O, Obrador G, Pannu N, Parikh CR, Perkovic V, Pollock C, Stenvinkel P, Tuttle KR, Wheeler DC, Eckardt KU; ISN Global Kidney Health Summit participants.

Lancet. 2017 Oct 21;390(10105):1888-1917. doi: 10.1016/S0140-6736(17)30788-2. Epub 2017 Apr 20. Review.

PMID:
28434650
23.

Cigarette smoking and cardio-renal events in patients with atherosclerotic renal artery stenosis.

Drummond CA, Brewster PS, He W, Ren K, Xie Y, Tuttle KR, Haller ST, Jamerson K, Dworkin LD, Cutlip DE, Murphy TP, D'Agostino RB Sr, Henrich WL, Tian J, Shapiro JI, Cooper CJ.

PLoS One. 2017 Mar 17;12(3):e0173562. doi: 10.1371/journal.pone.0173562. eCollection 2017.

24.

Dietary strategies for cardiovascular health.

Dieter BP, Tuttle KR.

Trends Cardiovasc Med. 2017 Jul;27(5):295-313. doi: 10.1016/j.tcm.2016.12.007. Epub 2016 Dec 31. Review.

PMID:
28161146
25.

Back to the Future: Glomerular Hyperfiltration and the Diabetic Kidney.

Tuttle KR.

Diabetes. 2017 Jan;66(1):14-16. doi: 10.2337/dbi16-0056. No abstract available.

26.

Preserving Self: Medication-Taking Practices and Preferences of Older Adults With Multiple Chronic Medical Conditions.

Vandermause R, Neumiller JJ, Gates BJ, David P, Altman M, Healey DJ, Benson P, Sunwold D, Burton G, Tuttle KR, Corbett CF.

J Nurs Scholarsh. 2016 Nov;48(6):533-542. doi: 10.1111/jnu.12250.

PMID:
27802372
27.

Effects of once-weekly dulaglutide on kidney function in patients with type 2 diabetes in phase II and III clinical trials.

Tuttle KR, McKinney TD, Davidson JA, Anglin G, Harper KD, Botros FT.

Diabetes Obes Metab. 2017 Mar;19(3):436-441. doi: 10.1111/dom.12816. Epub 2016 Nov 24.

28.

Relationship of Albuminuria and Renal Artery Stent Outcomes: Results From the CORAL Randomized Clinical Trial (Cardiovascular Outcomes With Renal Artery Lesions).

Murphy TP, Cooper CJ, Pencina KM, D'Agostino R, Massaro J, Cutlip DE, Jamerson K, Matsumoto AH, Henrich W, Shapiro JI, Tuttle KR, Cohen DJ, Steffes M, Gao Q, Metzger DC, Abernethy WB, Textor SC, Briguglio J, Hirsch AT, Tobe S, Dworkin LD.

Hypertension. 2016 Nov;68(5):1145-1152. Epub 2016 Sep 19.

29.

Immunity and inflammation in diabetic kidney disease: translating mechanisms to biomarkers and treatment targets.

Pichler R, Afkarian M, Dieter BP, Tuttle KR.

Am J Physiol Renal Physiol. 2017 Apr 1;312(4):F716-F731. doi: 10.1152/ajprenal.00314.2016. Epub 2016 Aug 24. Review.

30.

Serum amyloid a and risk of death and end-stage renal disease in diabetic kidney disease.

Dieter BP, McPherson SM, Afkarian M, de Boer IH, Mehrotra R, Short R, Barbosa-Leiker C, Alicic RZ, Meek RL, Tuttle KR.

J Diabetes Complications. 2016 Nov - Dec;30(8):1467-1472. doi: 10.1016/j.jdiacomp.2016.07.018. Epub 2016 Jul 27.

31.

Medication Intervention for Chronic Kidney Disease Patients Transitioning from Hospital to Home: Study Design and Baseline Characteristics.

Alicic RZ, Short RA, Corbett CL, Neumiller JJ, Gates BJ, Daratha KB, Barbosa-Leiker C, McPherson S, Chaytor NS, Dieter BP, Setter SM, Tuttle KR.

Am J Nephrol. 2016;44(2):122-9. doi: 10.1159/000447019. Epub 2016 Aug 4.

32.

JAK inhibition in the treatment of diabetic kidney disease.

Brosius FC, Tuttle KR, Kretzler M.

Diabetologia. 2016 Aug;59(8):1624-7. doi: 10.1007/s00125-016-4021-5. Epub 2016 Jun 22. Review.

33.

Association Between Prescription Opioid Use and Biomarkers of Kidney Disease in US Adults.

Barbosa-Leiker C, McPherson S, Daratha K, Alicic R, Short R, Dieter B, Chaytor N, Roll J, Tuttle KR.

Kidney Blood Press Res. 2016;41(4):365-73. doi: 10.1159/000443436. Epub 2016 Jun 20.

34.

Effects of Stenting for Atherosclerotic Renal Artery Stenosis on eGFR and Predictors of Clinical Events in the CORAL Trial.

Tuttle KR, Dworkin LD, Henrich W, Greco BA, Steffes M, Tobe S, Shapiro JI, Jamerson K, Lyass A, Pencina K, Massaro JM, D'Agostino RB Sr, Cutlip DE, Murphy TP, Cooper CJ.

Clin J Am Soc Nephrol. 2016 Jul 7;11(7):1180-8. doi: 10.2215/CJN.10491015. Epub 2016 May 25.

35.

The Surging Tide of Diabetes: Implications for Nephrology.

de Boer IH, Afkarian M, Tuttle KR.

Am J Kidney Dis. 2016 Mar;67(3):364-6. doi: 10.1053/j.ajkd.2015.12.002. Epub 2015 Dec 23. No abstract available.

36.

Complete Remission in the Nephrotic Syndrome Study Network.

Gipson DS, Troost JP, Lafayette RA, Hladunewich MA, Trachtman H, Gadegbeku CA, Sedor JR, Holzman LB, Moxey-Mims MM, Perumal K, Kaskel FJ, Nelson PJ, Tuttle KR, Bagnasco SM, Hogan MC, Dell KM, Appel GB, Lieske JC, Ilori TO, Sethna CB, Fervenza FC, Hogan SL, Nachman PH, Rosenberg AZ, Greenbaum LA, Meyers KE, Hewitt SM, Choi MJ, Kopp JB, Zhdanova O, Hodgin JB, Johnstone DB, Adler SG, Avila-Casado C, Neu AM, Hingorani SR, Lemley KV, Nast CC, Brady TM, Barisoni-Thomas L, Fornoni A, Jennette JC, Cattran DC, Palmer MB, Gibson KL, Reich HN, Mokrzycki MH, Sambandam KK, Zilleruelo GE, Licht C, Sampson MG, Song P, Mariani LH, Kretzler M.

Clin J Am Soc Nephrol. 2016 Jan 7;11(1):81-9. doi: 10.2215/CJN.02560315. Epub 2015 Dec 10.

37.

Renal Artery Stent Outcomes: Effect of Baseline Blood Pressure, Stenosis Severity, and Translesion Pressure Gradient.

Murphy TP, Cooper CJ, Matsumoto AH, Cutlip DE, Pencina KM, Jamerson K, Tuttle KR, Shapiro JI, D'Agostino R, Massaro J, Henrich W, Dworkin LD.

J Am Coll Cardiol. 2015 Dec 8;66(22):2487-94. doi: 10.1016/j.jacc.2015.09.073.

38.

Novel Therapies for Diabetic Kidney Disease: Storied Past and Forward Paths.

Dieter BP, Alicic RZ, Meek RL, Anderberg RJ, Cooney SK, Tuttle KR.

Diabetes Spectr. 2015 Aug;28(3):167-74. doi: 10.2337/diaspect.28.3.167.

39.

Diabetic Kidney Disease: A Call to Action: Preface.

Tuttle KR.

Diabetes Spectr. 2015 Aug;28(3):158-60. doi: 10.2337/diaspect.28.3.158. No abstract available.

40.

Serum amyloid A and inflammation in diabetic kidney disease and podocytes.

Anderberg RJ, Meek RL, Hudkins KL, Cooney SK, Alpers CE, Leboeuf RC, Tuttle KR.

Lab Invest. 2015 Jun;95(6):697. doi: 10.1038/labinvest.2015.38. No abstract available.

41.

Effect of ruboxistaurin on albuminuria and estimated GFR in people with diabetic peripheral neuropathy: results from a randomized trial.

Tuttle KR, McGill JB, Bastyr EJ 3rd, Poi KK, Shahri N, Anderson PW.

Am J Kidney Dis. 2015 Apr;65(4):634-6. doi: 10.1053/j.ajkd.2014.11.024. Epub 2015 Jan 22. No abstract available.

PMID:
25618186
42.

Serum amyloid A and inflammation in diabetic kidney disease and podocytes.

Anderberg RJ, Meek RL, Hudkins KL, Cooney SK, Alpers CE, Leboeuf RC, Tuttle KR.

Lab Invest. 2015 Mar;95(3):250-62. doi: 10.1038/labinvest.2014.163. Epub 2014 Dec 22. Erratum in: Lab Invest. 2015 Jun;95(6):697.

43.

Diabetic kidney disease: a report from an ADA Consensus Conference.

Tuttle KR, Bakris GL, Bilous RW, Chiang JL, de Boer IH, Goldstein-Fuchs J, Hirsch IB, Kalantar-Zadeh K, Narva AS, Navaneethan SD, Neumiller JJ, Patel UD, Ratner RE, Whaley-Connell AT, Molitch ME.

Am J Kidney Dis. 2014 Oct;64(4):510-33. doi: 10.1053/j.ajkd.2014.08.001.

PMID:
25257325
44.

Diabetic kidney disease: a report from an ADA Consensus Conference.

Tuttle KR, Bakris GL, Bilous RW, Chiang JL, de Boer IH, Goldstein-Fuchs J, Hirsch IB, Kalantar-Zadeh K, Narva AS, Navaneethan SD, Neumiller JJ, Patel UD, Ratner RE, Whaley-Connell AT, Molitch ME.

Diabetes Care. 2014 Oct;37(10):2864-83. doi: 10.2337/dc14-1296.

45.

Use of renin-angiotensin inhibitors in people with renal artery stenosis.

Evans KL, Tuttle KR, Folt DA, Dawson T, Haller ST, Brewster PS, He W, Jamerson K, Dworkin LD, Cutlip DE, Murphy TP, D'Agostino RB Sr, Henrich W, Cooper CJ.

Clin J Am Soc Nephrol. 2014 Jul;9(7):1199-206. doi: 10.2215/CJN.11611113. Epub 2014 Jun 5.

46.

Bardoxolone methyl in type 2 diabetes and advanced chronic kidney disease.

Himmelfarb J, Tuttle KR.

N Engl J Med. 2014 May 1;370(18):1768-9. doi: 10.1056/NEJMc1400872. No abstract available.

PMID:
24804308
47.

Urinary excretion of RAS, BMP, and WNT pathway components in diabetic kidney disease.

Afkarian M, Hirsch IB, Tuttle KR, Greenbaum C, Himmelfarb J, de Boer IH.

Physiol Rep. 2014 May 2;2(5):e12010. doi: 10.14814/phy2.12010. Print 2014.

48.

Novel therapies for diabetic kidney disease.

Alicic RZ, Tuttle KR.

Adv Chronic Kidney Dis. 2014 Mar;21(2):121-33. doi: 10.1053/j.ackd.2014.01.007. Review.

PMID:
24602462
49.

Observational study of kidney function and albuminuria in patients with type 2 diabetes treated with exenatide BID versus insulin glargine.

Pawaskar M, Tuttle KR, Li Q, Best JH, Anderson PW.

Ann Pharmacother. 2014 May;48(5):571-6. doi: 10.1177/1060028013520597. Epub 2014 Feb 4.

PMID:
24497624
50.

Stenting and medical therapy for atherosclerotic renal-artery stenosis.

Cooper CJ, Murphy TP, Cutlip DE, Jamerson K, Henrich W, Reid DM, Cohen DJ, Matsumoto AH, Steffes M, Jaff MR, Prince MR, Lewis EF, Tuttle KR, Shapiro JI, Rundback JH, Massaro JM, D'Agostino RB Sr, Dworkin LD; CORAL Investigators.

N Engl J Med. 2014 Jan 2;370(1):13-22. doi: 10.1056/NEJMoa1310753. Epub 2013 Nov 18.

Supplemental Content

Loading ...
Support Center